TY - JOUR
T1 - Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design
AU - Ghassemi, Saba
AU - Martinez-Becerra, Francisco J.
AU - Master, Alyssa M.
AU - Richman, Sarah A.
AU - Heo, David
AU - Leferovich, John
AU - Tu, Yitao
AU - García-Cañaveras, Juan Carlos
AU - Ayari, Asma
AU - Lu, Yinan
AU - Wang, Ai
AU - Rabinowitz, Joshua D.
AU - Milone, Michael C.
AU - June, Carl H.
AU - O'Connor, Roddy S.
N1 - Funding Information:
This work was supported by an NIH grant RO1CA226983-02 awarded to C.H.J. and R.S.O’C., a St. Baldrick's Foundation Scholar Award ( 587296 ) and a National Blood Foundation (NBF) Early Career Scientific Research Grant to S.G., a St. Baldrick's Foundation Scholar Award ( 524831 ) and an NIH/NCI CHOP Cancer Center K12CA076932 Award to S.R., as well as funding support by Nucleus Biologics . We thank Drs. Don Siegel, Bruce Levine, and Saar Gill and also Jai Patel, as well as David Sheehan, for helpful discussions.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/9/11
Y1 - 2020/9/11
N2 - Effective chimeric antigen receptor (CAR)-T cell therapy is dependent on optimal cell culture methods conducive to the activation and expansion of T cells ex vivo, as well as infection with CAR. Media formulations used in CAR-T cell manufacturing have not been optimized for gene delivery, cell expansion, and overall potency. Bioactive components and derivatives that support the generation of functionally-competent T cell progeny with long-lasting persistence are largely undefined. Current media formulations rely on fetal bovine serum (FBS) or human serum (HS), which suffer from a lack of consistency or supply issues. We recognize that components of blood cellular fractions that are absent in serum may have therapeutic value. Here we investigate whether a concentrated growth factor extract, purified from human transfusion grade whole blood fractions, and marketed as PhysiologixTM xeno-free (XF) hGFC (Phx), supports CAR-T cell expansion and function. We show that Phx supports T cell proliferation in clinical and research-grade media. We also show that Phx treatment enhances lentiviral-mediated gene expression across a wide range of multiplicity of infections (MOIs). We compared the ability of anti-GD-2 CAR-T cells expanded ex vivo in medium conditioned with either Phx or HS to clear tumor burden in a human xenograft model of neuroblastoma. We show that T cells expanded in Phx have superior engraftment and potency in vivo, as well as CAR-induced cytolytic activity in vitro. Metabolomic profiling revealed several factors unique to Phx that may have relevance for CAR-T cell preclinical discovery, process development, and manufacturing. In particular, we show that carnosine, a biogenic amine modestly enriched in Phx relative to HS, enhances lentiviral gene delivery in activated T cells. By limiting extracellular acidification, carnosine enhances the metabolic fitness of T cells, shifting their metabolic profile from an acidic, stressed state toward an oxidative, energetic state. These findings are very informative regarding potential derivatives to include in medium customized for gene delivery and overall potency for T cell adoptive immunotherapies.
AB - Effective chimeric antigen receptor (CAR)-T cell therapy is dependent on optimal cell culture methods conducive to the activation and expansion of T cells ex vivo, as well as infection with CAR. Media formulations used in CAR-T cell manufacturing have not been optimized for gene delivery, cell expansion, and overall potency. Bioactive components and derivatives that support the generation of functionally-competent T cell progeny with long-lasting persistence are largely undefined. Current media formulations rely on fetal bovine serum (FBS) or human serum (HS), which suffer from a lack of consistency or supply issues. We recognize that components of blood cellular fractions that are absent in serum may have therapeutic value. Here we investigate whether a concentrated growth factor extract, purified from human transfusion grade whole blood fractions, and marketed as PhysiologixTM xeno-free (XF) hGFC (Phx), supports CAR-T cell expansion and function. We show that Phx supports T cell proliferation in clinical and research-grade media. We also show that Phx treatment enhances lentiviral-mediated gene expression across a wide range of multiplicity of infections (MOIs). We compared the ability of anti-GD-2 CAR-T cells expanded ex vivo in medium conditioned with either Phx or HS to clear tumor burden in a human xenograft model of neuroblastoma. We show that T cells expanded in Phx have superior engraftment and potency in vivo, as well as CAR-induced cytolytic activity in vitro. Metabolomic profiling revealed several factors unique to Phx that may have relevance for CAR-T cell preclinical discovery, process development, and manufacturing. In particular, we show that carnosine, a biogenic amine modestly enriched in Phx relative to HS, enhances lentiviral gene delivery in activated T cells. By limiting extracellular acidification, carnosine enhances the metabolic fitness of T cells, shifting their metabolic profile from an acidic, stressed state toward an oxidative, energetic state. These findings are very informative regarding potential derivatives to include in medium customized for gene delivery and overall potency for T cell adoptive immunotherapies.
UR - http://www.scopus.com/inward/record.url?scp=85088998737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088998737&partnerID=8YFLogxK
U2 - 10.1016/j.omtm.2020.07.008
DO - 10.1016/j.omtm.2020.07.008
M3 - Article
C2 - 32775494
AN - SCOPUS:85088998737
SN - 2329-0501
VL - 18
SP - 595
EP - 606
JO - Molecular Therapy - Methods and Clinical Development
JF - Molecular Therapy - Methods and Clinical Development
ER -